A phase 3. open-label study evaluating the long-term safety and efficacy of VX445 combination therapy in subjects with Cystic Fibrosis who are heterozygous for the F508del mutation and a gating or residual function mutation (F/G and F/RF genotypes)

Project Details

StatusFinished
Effective start/end date8/08/1931/12/20

Funding

  • Vertex: A$11,573.00
  • Vertex: A$17,438.00
  • Vertex: A$1,128.00
  • Vertex: A$3,770.00
  • Vertex: A$35,465.00
  • Vertex: A$5,663.00
  • Vertex: A$9,649.00
  • Vertex: A$3,735.00
  • Vertex: A$3,988.00
  • Vertex: A$564.00
  • Vertex: A$1,128.00
  • Vertex: A$5,910.00
  • Vertex: A$3,670.00
  • Vertex: A$9,240.00